MC

Mark Carthy

Mark Carthy is an accomplished professional with extensive experience in venture capital, private equity, and commercial real estate, currently serving as Managing Partner at Orion Equity Partners, LLC since January 2008. With a notable role as Chairman at Antolrx, Inc. since March 2014, Mark Carthy has been instrumental in drug discovery and development. Additional positions include membership with Walnut Ventures and Mass Medical Angels, the latter focusing on life science and healthcare investments. Mark serves as an advisor on the Industrial Advisory Board for the Chemical Engineering Department at University College Dublin. Previous board memberships include the Earthwatch Institute and Rexahn Pharmaceuticals, highlighting a commitment to both environmental and healthcare advancements. Educational credentials include an MBA from Harvard Business School and a Master of Science in Chemical Engineering from Missouri University of Science and Technology, complemented by a Bachelor of Engineering in Chemical Engineering from UCD.

Location

Boston, United States

Links

Previous companies


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices


Mass Medical Angels

Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Our goal is to provide money and mentoring to the life science community to achieve superior returns for our group, and more clinical innovation for the community. Our focus is on early stage life science companies looking to raise $250K to $3.0M. Depending on the amount of funding needed, we can fund all or a portion of the round, and will work closely with other angel groups or venture funds in the area to complete the round. We are looking for companies that are extremely capital efficient opportunities where our funds will lead to significant step-ups in valuation to avoid unfavorable future funding rounds.


Headquarters

United States

Employees

51-200

Links